Lodestone’s biosensor and reader opens the door for a broad spectrum of longitudinal in vivo assays in the tumor microenvironment. Our small-animal system and in vivo assay technology accelerates cancer research. Lodestone's products are for research use only.
Looking for a particular Lodestone Biomedical employee's phone or email?
The Lodestone Biomedical annual revenue was $3 million in 2026.
Brendan Flynn is the CEO of Lodestone Biomedical.
4 people are employed at Lodestone Biomedical.
Lodestone Biomedical is based in Lebanon, New Hampshire.
The NAICS codes for Lodestone Biomedical are [54171, 541, 541714, 54, 5417].
The SIC codes for Lodestone Biomedical are [87, 873].